- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CureVac NV (CVAC)
CureVac NV stock price live, this page displays NASDAQ CVAC stock exchange data. View the CVAC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CureVac NV real time stock price chart below.
What Is the CureVac NV Stock Price Today?
The CureVac NV stock price today is 5.440.
What Is the Stock Symbol for CureVac NV?
The stock ticker symbol for CureVac NV is CVAC.
Is CVAC the Same as $CVAC?
$CVAC is a common way to refer to the CureVac NV ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does CureVac NV Trade On?
CureVac NV is listed and trades on the NASDAQ stock exchange.
Is CureVac NV a Good Stock to Buy?
Determining whether CureVac NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current CureVac NV share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CVAC quote. (ISIN: NL0015436031)
What Is the CureVac NV Stock Price Today?
The CureVac NV stock price today is 5.440.
What Is the Stock Symbol for CureVac NV?
The stock ticker symbol for CureVac NV is CVAC.
Is CVAC the Same as $CVAC?
$CVAC is a common way to refer to the CureVac NV ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does CureVac NV Trade On?
CureVac NV is listed and trades on the NASDAQ stock exchange.
Is CureVac NV a Good Stock to Buy?
Determining whether CureVac NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current CureVac NV share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CVAC quote. (ISIN: NL0015436031)
5.440
-0.050(-0.91%)
Closed·
After Hours
5.440+0.010(+0.184%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.410
5.550
52 wk Range
2.370
5.720
CVAC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CVAC is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.4105.550
52 wk Range
2.3705.720
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CVAC Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
5.928
Upside
+8.97%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
CureVac NV Company Profile
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
CureVac NV SWOT Analysis
Valuation Insights | Analysts set price targets ranging from $10 to $16, reflecting varied perspectives on CureVac's potential amid its pivotal year of clinical advancements and IP litigation outcomes |
Catalysts on Horizon | Anticipate key milestones in 2025-2026, including GBM vaccine results and ExPEC IND filing, potentially reshaping CureVac's market position and investor sentiment |
Financial Fortitude | With a robust cash position of €438 million funding operations into 2028, CureVac demonstrates financial stability amidst market challenges and ongoing clinical developments |
mRNA Pioneer's Edge | CureVac's innovative mRNA platform underpins a diverse pipeline, including promising vaccine candidates for glioblastoma and ExPEC, positioning it at the forefront of genetic medicine |
CureVac NV Earnings Call Summary for Q3/2024
- Q3 revenue soared to €493.9M, driven by €1.45B GSK licensing deal; strong cash position of €551M reported
- Strategic shift to oncology and infectious diseases; 30% workforce reduction planned to enhance efficiency
- Advancing mRNA cancer vaccines; new program for urinary tract infections shows promise in preclinical studies
- Operating expenses expected to rise 30%+ in 2024; aim to decrease by over 30% starting 2025
- Axel Malkomes appointed as new CFO; U.S. court case scheduled for March 2025 regarding ongoing litigation
Last Updated: 11/13/2024, 04:54 AM
Read Full TranscriptCompare CVAC to Peers and Sector
Metrics to compare | CVAC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCVACPeersSector | |
|---|---|---|---|---|
P/E Ratio | 5.9x | −2.0x | −0.5x | |
PEG Ratio | 0.04 | 0.00 | 0.00 | |
Price / Book | 1.6x | 1.0x | 2.6x | |
Price / LTM Sales | 2.0x | 4.8x | 3.0x | |
Upside (Analyst Target) | −21.9% | 124.7% | 52.4% | |
Fair Value Upside | Unlock | 13.7% | 8.7% | Unlock |
Analyst Ratings
2 Buy
4 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.928
(+8.97% Upside)
Earnings
Latest Release
May 20, 2025
EPS / Forecast
-0.23 / -0.1612
Revenue / Forecast
900.00K / --
People Also Watch
FAQ
What Is the CureVac NV (CVAC) Stock Price Today?
The CureVac NV stock price today is 5.44
What Stock Exchange Does CureVac NV Trade On?
CureVac NV is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for CureVac NV?
The stock symbol for CureVac NV is "CVAC."
What Is the CureVac NV Market Cap?
As of today, CureVac NV market cap is 1.22B.
What Is CureVac NV's Earnings Per Share (TTM)?
The CureVac NV EPS (TTM) is 0.80.
When Is the Next CureVac NV Earnings Date?
CureVac NV will release its next earnings report on Aug 14, 2025.
From a Technical Analysis Perspective, Is CVAC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has CureVac NV Stock Split?
CureVac NV has split 0 times.
How Many Employees Does CureVac NV Have?
CureVac NV has 904 employees.
What is the current trading status of CureVac NV (CVAC)?
As of Jun 22, 2025, CureVac NV (CVAC) is trading at a price of 5.44, with a previous close of 5.49. The stock has fluctuated within a day range of 5.41 to 5.55, while its 52-week range spans from 2.37 to 5.72.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.